InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
September 01, 2022 17:18 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
August 31, 2022 17:30 ET | Interpace Biosciences, Inc.
Interpace Transitions to focused Molecular Diagnostics BusinessDisposition of Pharma Services Expected to Improve Operating Cash Flow by nearly $5 million Annually PARSIPPANY, NJ, Aug. 31, 2022 ...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
August 15, 2022 16:05 ET | Interpace Biosciences, Inc.
 ●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
May 16, 2022 16:15 ET | Interpace Biosciences, Inc.
 ●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE)...
InterpaceBiosciences_New Logo.png
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
May 11, 2022 08:30 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
March 31, 2022 16:15 ET | Interpace Biosciences, Inc.
 ●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year  ●2021 Full Year Net Loss Improved $11.5 Million vs Prior...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests
February 22, 2022 09:00 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests
January 28, 2022 19:35 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering
January 12, 2022 16:41 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
January 03, 2022 17:07 ET | Interpace Biosciences, Inc.
Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”)...